MONTREAL--(BUSINESS WIRE)--Today Inversago Pharma Inc., a preclinical-stage biotech company developing novel CB1 blockers for the treatment of targeted metabolic disorders, announced the appointment of two seasoned pharma executives in line with the Company’s aim to attract first-class industry leaders for their guidance and expertise.
Inversago welcomes Dennis Kim, MD, MBA and Tara Nickerson, PhD, MBA as new independent directors
Dr. Dennis Kim’s career spans over 20 years of drug/product development in the areas of endocrinology and metabolic diseases, including obesity and type 2 diabetes (T2D). Dr. Kim was formerly CMO at Zafgen where he brought beloranib up to pivotal Phase 3 trial for the treatment of Prader-Willi Syndrome (PWS). Dr. Kim also brings to Inversago a proven set of skills as executive officer in public and private companies, successful track record of private and public fundraising, and effective alliance partnership development with various major pharmaceutical companies.
“I am thrilled to join Inversago’s endeavor in advancing and developing CB1 blockers in the field of endocrine and metabolic disorders. I believe my background and area of expertise will be an effective complement to the company’s already strong R&D strategy and execution,” said Dr. Kim. “I am inspired and motivated by the plight of patients who suffer from devastating metabolic disorders and Inversago is uniquely positioned, as the leader in CB1 receptor blocking technology, to deliver compelling medicines to those in need.”
Dr. Tara Nickerson is an accomplished executive with more than 20 years of experience in building biotech companies from start-up to commercialization stages. She currently serves as Chief Business Officer at Maze Therapeutics. Dr. Nickerson brings an expertise in corporate and business development as well as strong transactional and operational experience, and her proven track record includes a number of significant partnerships. She also played a key role in forming Prothena and launching Maze, two pharmaceutical companies.
“Inversago’s technology leverages decades of CB1 research to develop next generation therapies for patients having diseases with significant unmet need. I am excited to partner with the growing Inversago team as the company executes this vision”, said Dr. Nickerson.
“We are privileged to have Dennis and Tara join our Board of Directors, thus broadening our clinical and business development capabilities. Both appointments are pivotal as the company grows into its next stage of development”, added François Ravenelle, CEO of Inversago.
About Inversago Pharma
A specialized, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome, diabetes, obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH). Inversago’s technology addresses limits associated to first generation CB1 blockers, allowing the company to exploit their full medical potential. For more information, visit www.inversago.com.